GlassScriptPhysician profile
Brooke Plewinski
NPI 1902068984
$8,123.34
in general payments reported to CMS, 2019-2025
53 companies · $45.76 in 2025
The $45.76 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,066 · 2022: $2,900 · 2023: $3,036 · 2024: $76.22 · 2025: $45.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,082 · Honoraria: $1,000 · Education: $76.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,081.66 |
| Honoraria | $1,000.00 |
| Education | $76.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $1,968.31 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| E.R. Squibb & Sons, L.L.C. | $523.96 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $479.02 | 2021-2023 | Keytruda, Verquvo, Lynparza |
| Astrazeneca Pharmaceuticals LP | $458.62 | 2021-2023 | Tagrisso |
| Novartis Pharmaceuticals Corporation | $428.12 | 2021-2023 | |
| Genentech USA, INC. | $427.46 | 2021-2023 | Venclexta, Tecentriq |
| Amgen INC. | $373.48 | 2021-2023 | Lumakras, Nplate, Xgeva |
| Takeda Pharmaceuticals U.S.A., INC. | $256.73 | 2021-2024 | Fruzaqla |
| Celgene Corporation | $250.68 | 2022-2023 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $227.56 | 2021-2023 | Imbruvica |
| Gilead Sciences, INC. | $204.29 | 2021-2025 | Trodelvy |
| Seagen INC. | $183.72 | 2021-2023 | Padcev |
| Lilly USA, LLC | $159.78 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $155.40 | 2021-2023 | |
| Daiichi Sankyo INC. | $141.96 | 2021-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Plewinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.